Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents.
about
Escitalopram versus other antidepressive agents for depressionCanadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disordersPolypharmacy patterns: unravelling systematic associations between prescribed medicationsIdentification and treatment of depression in minority populations.Position paper on the importance of psychosocial factors in cardiology: Update 2013SSRIs increase risk of blood transfusion in patients admitted for hip surgery.Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial.Treatment considerations for patients with neuropathic pain and other medical comorbidities.Selective serotonin reuptake inhibitors and gastrointestinal bleeding: a case-control study.Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients.Observational study of upper gastrointestinal tract bleeding events in patients taking duloxetine and nonsteroidal anti-inflammatory drugs: a case-control analysis.Antidepressant use and risk of adverse outcomes in older people: population based cohort study.Risk of intracranial haemorrhage in antidepressant users with concurrent use of non-steroidal anti-inflammatory drugs: nationwide propensity score matched studyInflammation and depression: combined use of selective serotonin reuptake inhibitors and NSAIDs or paracetamol and psychiatric outcomes.Use of SSRI, But Not SNRI, Increased Upper and Lower Gastrointestinal Bleeding: A Nationwide Population-Based Cohort Study in Taiwan.Upper gastrointestinal bleeding: incidence, etiology and outcomes in a population-based settingVenlafaxine-Induced Bruising: A Case ReportDepression and anxiety in inflammatory bowel disease: a review of comorbidity and management.Population impact of regulatory activity restricting prescribing of COX-2 inhibitors: ecological studyEffect of selective serotonin reuptake inhibitors on bleeding risk in patients with atrial fibrillation taking warfarin.Psychiatric comorbidity in the treatment of patients with inflammatory bowel disease.Concomitant use of SSRIs, NSAIDs/aspirin and gastroprotective drugs among residents of long-term care facilities: a medical record review.Clinically significant drug interactions with newer antidepressants.Clinically relevant drug interactions in anxiety disorders.Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case-control study in a new general practice database.Defining a reference set to support methodological research in drug safety.Effects of depressive and other psychiatric disorders on anticoagulation control in a pharmacist-managed anticoagulation clinic.Levomilnacipran: a newly approved drug for treatment of major depressive disorder.Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis.Safety of selective serotonin reuptake inhibitor treatment in recovering stroke patients.A Pharmacoepidemiology Database System for Monitoring Risk Due to the Use of Medicines by New Zealand Primary Care Patients.Selective Serotonin Reuptake Inhibitors and Operative Bleeding Risk: A Review of the Literature.The Risk of Thromboembolism in Users of Antidepressants and Antipsychotics.Concomitant NSAID use during antipsychotic treatment and risk of 2-year relapse - a population-based study of 16,253 incident patients with schizophrenia.Evaluation of anti-inflammatory activity, effect on blood pressure & gastric tolerability of antidepressants.Editorial: venlafaxine for functional chest pain: hope or hype?Treating depression in older adults with dementia.Detection and treatment of post stroke depression: results from the registry of the Canadian stroke network.Helicobacter pylori and risk of upper gastrointestinal bleeding among users of selective serotonin reuptake inhibitors.Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding.
P2860
Q24241065-D0B49189-D2A9-4F41-94D9-4CB49BBCFED8Q27009995-CFF2EEE7-0A92-4928-BC3B-5E42F756599BQ28537875-091D986A-C830-42A2-A015-C796F8871972Q30413593-4964720F-DF5A-4A46-AA5D-BDBA39614E71Q33576193-7ABA2D04-36FE-46D9-BF81-CFCBD904CBC9Q33644329-49CD338B-9D34-40A8-92F2-0DE6212596D7Q33734249-D5BF116B-7008-41FD-839F-2417CFD7873EQ33747271-06A8C401-DB03-4A5A-97EA-4FF38D42A808Q33916845-5F0D20FF-6897-4962-8C31-24FDEA4E881EQ34182611-C6EC9471-B829-4C0E-A401-6F9D95DBAFF5Q34462222-AD5C9196-B1E7-4F93-A111-83EACCDB94EBQ35144173-C54D7314-FA0D-4431-85BD-56FB845783BDQ35849142-DB3CE2D2-68F8-46FE-9714-920768F834FEQ36023793-23480991-49E2-4450-8611-3BE147F9C9A2Q36299281-FB945984-3CD6-4FF1-9C26-44FE42C11B93Q36733540-AC2AA5D5-8BC1-44B3-BE30-68AA604330CBQ37281292-9D77E04C-EC98-44C7-92EC-412C29AD48EDQ37374868-3DEA4D64-D522-40AA-9241-134D3D30C4F1Q37471109-0EA189A5-589E-4D71-8045-25AE48B91D92Q37524726-5D226B25-00A0-4235-AD23-BCD93D59FE1BQ37682510-0E7B3C68-CE6B-40E0-87C6-E598749F45D4Q37848817-CD815795-EA6D-4498-8261-0BD7830BEE8EQ37968621-FC128A23-D83D-4FA6-BA69-29AC669D08C0Q37981951-02464FE1-F6F8-49CA-B377-2D30482D80CBQ38041462-9225A646-2F2C-4A9E-B822-A8A8A9AD40D6Q38156066-1FA6EF2A-AFAE-4A90-A276-27079A0ACE2EQ38164681-BC1CEB4D-4808-407B-AB2D-372B6820B0EBQ38187697-B6B4D347-A6B9-4F30-9A04-7F395D2582A0Q38207875-98C349D8-530A-49C7-823E-1FBD96AD9B46Q38402064-5F95A555-CA80-4464-8460-CD7A9BE68BE2Q38647547-3A2E63F5-C7A9-4789-9963-7823E0294C9EQ38967657-A3EB7AEF-2F3D-40C9-BDE5-6634F1B564EBQ40577573-75A72A71-A10C-4C3E-9B0A-83B271129C56Q40847189-4354065E-6BFE-46DF-BDAC-F58701CF62AEQ42592030-0A421512-1432-492F-ABD1-9F92E5436950Q42698067-1C379AE6-2C1C-4F0C-938F-BDB4C887C3E0Q43188859-332EB657-3470-4B20-B0CB-BD2763D924CEQ43816670-33122D6A-6585-47F2-8185-92C98A5E73E7Q43821335-82654324-ADBB-4F03-9699-8C9861BD97E9Q45832729-EE72E233-AC0C-4E1C-A6D2-BC7C8924D64D
P2860
Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents.
description
2008 nî lūn-bûn
@nan
2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Risk of upper gastrointestinal ...... ct of acid-suppressing agents.
@ast
Risk of upper gastrointestinal ...... ct of acid-suppressing agents.
@en
Risk of upper gastrointestinal ...... ct of acid-suppressing agents.
@nl
type
label
Risk of upper gastrointestinal ...... ct of acid-suppressing agents.
@ast
Risk of upper gastrointestinal ...... ct of acid-suppressing agents.
@en
Risk of upper gastrointestinal ...... ct of acid-suppressing agents.
@nl
prefLabel
Risk of upper gastrointestinal ...... ct of acid-suppressing agents.
@ast
Risk of upper gastrointestinal ...... ct of acid-suppressing agents.
@en
Risk of upper gastrointestinal ...... ct of acid-suppressing agents.
@nl
P1433
P1476
Risk of upper gastrointestinal ...... ct of acid-suppressing agents.
@en
P2093
Francisco J de Abajo
Luis A García-Rodríguez
P304
P356
10.1001/ARCHPSYC.65.7.795
P407
P577
2008-07-01T00:00:00Z